Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 8/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GNRHR | P30968 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30114922 | 1.00 | AGTR2 (0.37) | AGTR2PTGER4KMT2ATP53MAPT | |
| SCHEMBL2356746 | 0.87 | PTGER4 (0.48) | AGTR2PTGER4KMT2ATP53MAPT | |
| SCHEMBL1626400 | 0.86 | RAF1 (0.34) | AGTR2PPARG | |
| SCHEMBL21470223 | 0.84 | PTGER4 (0.37) | AGTR2PTGER4KMT2ATP53MAPT | |
| SCHEMBL30114744 | 0.84 | PTGER4 (0.37) | AGTR2PTGER4KMT2ATP53MAPT | |
| SCHEMBL21470221 | 0.84 | PTGER4 (0.37) | AGTR2PTGER4KMT2ATP53MAPT | |
| SCHEMBL30114904 | 0.84 | PTGER4 (0.37) | AGTR2PTGER4KMT2ATP53MAPT | |
| SCHEMBL2351917 | 0.84 | HRH3 (0.38) | AGTR2PTGER4TP53 | |
| SCHEMBL30114876 | 0.84 | HRH3 (0.38) | AGTR2PTGER4TP53 | |
| SCHEMBL1625175 | 0.83 | MAPT (0.35) | PTGER4MAPTGNRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066040-A1 | EP4 INHIBITORS AND USE THEREOF | ARRYS THERAPEUTICS INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240066040-A1 | EP4 INHIBITORS AND USE THEREOF | ARRYS THERAPEUTICS INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20210290641-A1 | EP4 INHIBITORS AND USE THEREOF | ASKAT INC. (JP) | 2021-09-23 | — | — | US | disclosed |
| US-10973834-B2 | EP4 inhibitors and use thereof | Arrys Therapeutics, Inc. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190314390-A1 | EP4 INHIBITORS AND USE THEREOF | ASKAT INC. (JP) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210290641-A1 | EP4 INHIBITORS AND USE THEREOF | PTGER4, EPB41, PTGER1 | AGTR2 3313/4885PTGER4 1/4885KMT2A 1165/4885 |
| US-20190314390-A1 | EP4 INHIBITORS AND USE THEREOF | PTGER4, EPB41, PTGER1 | AGTR2 3313/4885PTGER4 1/4885KMT2A 1165/4885 |
| US-10973834-B2 | EP4 inhibitors and use thereof | PTGER4, EPB41, PTGER1 | AGTR2 3313/4885PTGER4 1/4885KMT2A 1165/4885 |
| US-20240066040-A1 | EP4 INHIBITORS AND USE THEREOF | PTGER4, EPB41, PTGER1 | AGTR2 3313/4885PTGER4 1/4885KMT2A 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.